English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae

Kaplonek, P., Yao, L., Reppe, K., Voß, F., Kohler, T., Ebner, F., et al. (2022). A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae. Vaccine. doi:10.1016/j.vaccine.2021.12.068.

Item is

Basic

show hide
Genre: Journal Article

Files

show Files
hide Files
:
Preprint.pdf (Preprint), 528KB
Name:
Preprint.pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
:
Article.pdf (Publisher version), 2MB
 
File Permalink:
-
Name:
Article.pdf
Description:
-
Visibility:
Restricted (Max Planck Institute of Colloids and Interfaces, MTKG; )
MIME-Type / Checksum:
application/pdf
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
License:
-

Locators

show

Creators

show
hide
 Creators:
Kaplonek, Paulina1, Author              
Yao, Ling1, Author              
Reppe, Katrin, Author
Voß, Franziska, Author
Kohler, Thomas, Author
Ebner, Friederike, Author
Schäfer, Alexander, Author
Blohm, Ulrike, Author
Priegue, Patricia1, Author              
Bräutigam, Maria1, Author              
Pereira, Claney Lebev1, Author              
Parameswarappa, Sharavathi Guddehalli1, Author              
Emmadi, Madhu1, Author              
Ménová, Petra1, Author              
Witzenrath, Martin, Author
Hammerschmidt, Sven, Author
Hartmann, Susanne, Author
Sander, Leif E., Author
Seeberger, Peter H.1, Author              
Affiliations:
1Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society, ou_1863308              

Content

show
hide
Free keywords: Vaccines, Carbohydrate vaccines, Infectious diseases, Streptococcus pneumoniae, Carrier protein
 Abstract: Streptococcus pneumoniae (S. pneumoniae) infections are the leading cause of child mortality globally. Current vaccines fail to induce a protective immune response towards a conserved part of the pathogen, resulting in new serotypes causing disease. Therefore, new vaccine strategies are urgently needed. Described is a two-pronged approach combining S. pneumoniae proteins, pneumolysin (Ply) and pneumococcal surface protein A (PspA), with a precisely defined synthetic oligosaccharide, whereby the carrier protein acts as a serotype-independent antigen to provide additional protection. Proof of concept in mice and swine models revealed that the conjugates inhibited colonization of the nasopharynx, decreased the bacterial load and reduced disease severity in the bacteria challenge model. Immunization of piglets provided the first evidence for the immunogenicity and protective potential of synthetic glycoconjugate vaccine in a large animal model. A combination of synthetic oligosaccharides with proteins from the target pathogen opens the path to create broadly cross-protective (“universal”) pneumococcal vaccines.

Details

show
hide
Language(s): eng - English
 Dates: 2022-01-132022
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: DOI: 10.1016/j.vaccine.2021.12.068
BibTex Citekey: KAPLONEK2022
Other: MS angefragt 21.1.22 SN
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Vaccine
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Guildford, Surrey, UK : Elsevier
Pages: - Volume / Issue: - Sequence Number: - Start / End Page: - Identifier: ISSN: 0264-410X

Source 2

show
hide
Title: bioRxiv
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Cold Spring Harbor, NY : Cold Spring Harbor Laboratory
Pages: - Volume / Issue: - Sequence Number: 2021.07.29.454378 Start / End Page: - Identifier: ZDB: 2766415-6